---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-014934"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2023-02-09T23:59:59+00:00"
generated_at: "2026-06-19T20:38:31.889955+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Replimune Q3 net loss $39.7M; cash $616M; RP1 melanoma achieves 36% ORR in IGNYTE cohort

## Summary
- Net loss $39.7M for fiscal Q3 ended Dec 31, 2022 vs $29.7M YoY; R&D expenses rose to $30.3M.
- Raised ~$259M gross in upsized public offering; secured $200M non-dilutive debt facility ($30M drawn); cash runway into H2 2025.
- Topline data from CERPASS trial (RP1+cemiplimab in CSCC) delayed to Q3 2023 from prior H1 2023.
- IGNYTE cohort of RP1+Opdivo in anti-PD1 failed melanoma: 36% ORR, 20% CR in first 75 patients; target enrollment of 125 reached.
- Collaboration with Roche for RP2/3 in CRC and HCC; appointed Christopher Sarchi as CCO.

## SEC filing metadata
- accession: 0001104659-23-014934
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2023-02-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465923014934/0001104659-23-014934-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465923014934/tm235946d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-014934
- JSON: https://secwatch.observer/filing/0001104659-23-014934.json
- Plain text: https://secwatch.observer/filing/0001104659-23-014934.txt

## Key facts
- Earnings Releases
  Replimune Group, Inc. reported financial results for the fiscal third quarter ended December 31, 2022.
  - Period: the fiscal third quarter ended December 31, 2022
  - Result: reported results
  source text: On February 9, 2023, Replimune Group, Inc. issued a news release announcing its financial results for the third quarter ended December 31, 2022 and certain corporate updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737953/000110465923014934/0001104659-23-014934-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.